As AI advances genomic analyses, the potential for misuse grows, amplifying risks of discrimination and exploitation that could span generations. 23andMe’s struggles demonstrate that the ...

23andMe's stock plummeted after a 2023 data breach exposed millions of customer accounts. The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its ...

23andMe faced major hurdles in 2024, including a $30 million settlement related to compromised data. 23andMe is now restructuring its business operations to reduce costs and streamline operations ...

It remains unknown how many patients are affected by the incident. The Qilin ransomware group claims to have leaked 400 ...

Me still merchandises its ancestry, health analysis, and the Total Health annual package on a scale from $99 to $999 annually. Lemonaid entered the hot GLP-1 prescribing and support business in 2024, ...

From cloud chaos to clarity.” In this episode, AT&T’s Erian Laperi, Kristina Sutton, and Dan Wagner discuss transforming one ...

Two of the most popular brands are Ancestry and 23andMe. To learn more, we outlined the pros, cons and factors to consider. However, since this comparison was first published, 23andMe has ...

The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer ...

23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...

23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought virtual care startup Lemonaid in 2021 for $400 million.